Quartz·1 min read·medium
Novartis returns to sales growth as cancer and MS drugs offset Entresto's steep decline
✦AI Summary
Novartis achieved a 3% increase in net sales to $14.4 billion, exceeding market expectations. Strong performance in cancer and multiple sclerosis treatments helped offset the decline in sales for the drug Entresto.
Net sales rose 3% in dollars to $14.4 billion, beating estimates, while core operating profit held flat at $5.94 billion
businesshealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in